Dermatology Clinical Research Studies in Wilmington, NC

At Wilmington Dermatology Center, patients have the opportunity to participate in advanced dermatology clinical trials in Wilmington, NC, led by board-certified dermatologist Rosalyn George, M.D. Our experienced research team conducts dermatology research studies for medical, surgical, and cosmetic skin concerns, including acne, eczema, psoriasis, alopecia areata, injectable fillers, neurotoxins, and other innovative skin treatment studies.

With extensive experience across clinical dermatology and cosmetic clinical research, Dr. George and the Wilmington Dermatology Center team help evaluate the safety and effectiveness of emerging treatments while giving eligible participants access to research-based care. Whether you are interested in a psoriasis clinical trial in Wilmington, an eczema research study, an acne clinical trial, or injectable filler clinical research, our team can help determine whether a current or future study may be right for you.

Request an Appointment

Questions? Text Us

Become a Dermatology Clinical Trial Candidate in Wilmington, NC

Wilmington Dermatology Center offers patients the opportunity to participate in dermatology clinical research studies for medical and cosmetic skin concerns, including eczema, psoriasis, acne, injectables, and advanced skin treatment studies. Led by board-certified dermatologist Dr. Rosalyn George, our research team helps qualified participants access study-related dermatology treatments, evaluations, or products at no cost; some studies may also offer compensation for time and travel.

If you are searching for paid clinical trials near me, no-cost dermatology treatments, cosmetic research studies, an eczema clinical trial in NC, or a psoriasis study near Wilmington, our team can help determine whether you may qualify. Each participant completes a screening process, receives clear information about study requirements and time commitments, and is monitored throughout the study with patient safety and comfort as the priority.

Speak With Our Research Team

Trusted Dermatology Research Partner in Wilmington, NC

Wilmington Dermatology Center, led by board-certified dermatologist Dr. Rosalyn George, is recognized as a trusted dermatology clinical research site in Wilmington, NC. Our experienced research team has supported a wide range of dermatology research studies and clinical trials, with a strong track record of meeting enrollment goals, including difficult-to-recruit studies. With a diverse patient population and a detail-oriented approach, WDC is well positioned to help sponsors and CROs conduct high-quality dermatology research efficiently and responsibly.

Our clinical research process follows established study protocols, IRB oversight, patient confidentiality standards, and Good Clinical Practice principles. From screening and enrollment to patient communication and study coordination, our team is committed to accuracy, responsiveness, and participant safety. This commitment has made Wilmington Dermatology Center a valuable partner for clinical research organizations, sponsors, and patients seeking access to advanced dermatology research opportunities.

CRO Testimonial

“Dr. Rosalyn George at Wilmington Dermatology Center has established a center of excellence for research. She consistently reaches her enrollment target ahead of schedule and has been invaluable in filling difficult-to-recruit studies. She has a very diverse client base that allows her to recruit subjects for a variety of different studies. She leads an experienced, dedicated research team who is very detail-oriented and is one of the most responsive that I have had the pleasure to work with.”

— Senior Clinical Research Manager

Learn About Current Studies

Trusted Dermatology Research Partner in Wilmington, NC

CRO Testimonial

— Senior Clinical Research Manager

Learn About Current Studies

Ongoing and Currently Recruiting Dermatology Studies in Wilmington, NC

Wilmington Dermatology Center is currently enrolling participants for select dermatology clinical research studies in Wilmington, NC. Our research studies may include acne, eczema/atopic dermatitis, psoriasis, alopecia areata, and cosmetic clinical studies such as neurotoxins and injectable fillers. Participation may give qualified candidates access to investigational dermatology treatments, study-related care, and no-cost evaluations during the research process.

Acne Clinical Trials

Acne clinical trials may be available for teens and adults struggling with persistent breakouts, inflammatory acne, clogged pores, or acne that has not responded well to over-the-counter or prescription treatments. Qualified participants may be evaluated for research studies involving topical medications, oral treatments, or other acne therapies designed to improve active breakouts and overall skin clarity.

Eczema and Atopic Dermatitis Clinical Trials

Eczema and atopic dermatitis research studies may be available for patients experiencing chronic itching, redness, dry patches, irritation, or recurring flare-ups. These studies may evaluate new or existing treatment options intended to reduce inflammation, improve comfort, and help manage moderate to severe eczema symptoms.

Psoriasis Research Studies

Psoriasis clinical research studies may be available for adults with plaque psoriasis or recurring areas of thick, scaly, red, or inflamed skin. Eligible participants may have the opportunity to take part in studies evaluating dermatology treatments that target psoriasis symptoms and help advance care options for patients with chronic skin conditions.

Cosmetic Clinical Studies: Neurotoxins and Injectable Fillers

Wilmington Dermatology Center may also offer cosmetic clinical research studies involving neurotoxins and injectable fillers. These studies may evaluate treatments designed to improve the appearance of facial lines, wrinkles, volume loss, or other cosmetic concerns. Qualified participants are carefully screened to determine whether they are a good fit for the study requirements.

Alopecia Areata Research Studies

Alopecia areata clinical studies may be available for patients experiencing patchy hair loss or autoimmune-related hair shedding. Research studies may evaluate treatments designed to support hair regrowth and improve understanding of alopecia areata treatment options.

Request an Appointment

Text Us

Who May Qualify for a Dermatology Clinical Study?

Eligibility varies by study, but candidates are typically evaluated based on their age, medical history, current skin condition, symptom severity, previous treatments, and study-specific requirements. Some studies may include teens, while others may be limited to adults. Study length, visit schedule, treatment details, and possible compensation vary by research opportunity.

Frequently Asked Questions About Dermatology Clinical Trials

Who qualifies for psoriasis clinical trials?

Eligibility for psoriasis clinical trials depends on the type and severity of psoriasis, previous treatments, age, medical history, and the study’s specific requirements. A screening visit helps determine whether a patient may qualify.

Can teens participate in acne studies?

Some acne clinical trials may allow teen participants, depending on the study protocol and age requirements. A parent or guardian may need to provide consent for minors.

Are eczema clinical trials available for adults?

Yes, some eczema and atopic dermatitis studies may be available for adults with ongoing symptoms such as itching, redness, dryness, or recurring flare-ups.

Do clinical studies include compensation?

Compensation may be available for certain studies, but it depends on the specific research opportunity. The study team will review compensation, visit requirements, and expectations during the screening process.

How long do dermatology research studies last?

Study duration varies. Some dermatology studies may involve only a few visits, while others may require ongoing appointments over several weeks or months.

Interested in Participating?

If you are interested in acne clinical trials, eczema research studies, psoriasis clinical trials, alopecia areata studies, or cosmetic clinical research in Wilmington, NC, contact Wilmington Dermatology Center to learn more about currently recruiting studies and find out whether you may qualify.

Recent Dermatology Clinical Research Studies and Related Conditions

Wilmington Dermatology Center has participated in a wide range of dermatology clinical research studies focused on medical, cosmetic, and inflammatory skin conditions. Our research experience includes studies involving acne, psoriasis, eczema, alopecia areata, rosacea, melasma, hidradenitis suppurativa, cosmetic injectables, neurotoxins, and skin tightening treatments. These studies help advance dermatology care while giving qualified participants the opportunity to explore investigational or study-related treatment options.

Acne Research Studies

Acne clinical research studies may focus on new or improved treatments for mild, moderate, or severe acne. Acne can include clogged pores, blackheads, whiteheads, inflamed bumps, cysts, and acne-related discoloration or scarring. Research studies may evaluate topical medications, oral therapies, device-based treatments, or combination approaches designed to improve breakouts and skin clarity.

Actinic Keratosis Research Studies

Actinic keratosis is a common precancerous skin condition caused by long-term sun exposure. These rough, scaly patches often appear on the face, scalp, ears, neck, hands, or arms. Dermatology research studies for actinic keratosis may evaluate topical treatments, field therapies, or other approaches designed to treat visible lesions and sun-damaged skin.

Alopecia Areata Research Studies

Alopecia areata is an autoimmune condition that causes patchy or widespread hair loss on the scalp, face, or body. Research studies for alopecia areata may focus on treatments that target immune system activity and support hair regrowth. Participants may include patients with mild patchy hair loss or more extensive forms of the condition, depending on the study requirements.

Atopic Dermatitis / Eczema Research Studies

Atopic dermatitis, commonly called eczema, can cause dry, itchy, inflamed, cracked, or irritated skin. Eczema research studies may evaluate topical medications, oral treatments, injectable therapies, or other investigational options for patients with recurring or difficult-to-control symptoms. These studies help researchers better understand long-term eczema care and symptom relief.

Cosmetic Injectable Filler Research Studies

Cosmetic injectable filler studies may evaluate products designed to restore volume, soften lines, enhance facial contours, or improve the appearance of age-related volume loss. These studies may focus on treatment areas such as the cheeks, lips, jawline, chin, or smile lines. Eligibility depends on study goals, age requirements, skin condition, and treatment history.

Cosmetic Neurotoxin Research Studies

Cosmetic neurotoxin studies may evaluate treatments used to temporarily soften the appearance of dynamic wrinkles, including frown lines, forehead lines, and crow’s feet. Research may compare dosing, duration, safety, or patient satisfaction with study-related neurotoxin treatments. Qualified participants may receive study-related care under professional supervision.

Hand Dermatitis Research Studies

Hand dermatitis can cause redness, itching, scaling, cracking, burning, or painful irritation on the hands. It may be related to eczema, allergies, frequent handwashing, occupational exposure, or irritants. Clinical research studies for hand dermatitis may evaluate treatments designed to reduce inflammation, restore the skin barrier, and improve comfort during daily activities.

Melasma Research Studies

Melasma is a common pigmentation condition that causes brown or gray-brown patches, often on the cheeks, forehead, upper lip, or chin. Melasma treatment research may evaluate topical therapies, combination regimens, light-based treatments, or skincare approaches designed to improve uneven pigmentation and help manage recurrence.

Hidradenitis Suppurativa Research Studies

Hidradenitis suppurativa is a chronic inflammatory skin condition that may cause painful bumps, abscesses, drainage, scarring, and recurring flare-ups, commonly in areas such as the underarms, groin, buttocks, or under the breasts. Hidradenitis suppurativa clinical trials may evaluate treatments that target inflammation, reduce flare frequency, and improve quality of life.

Palmoplantar Pustulosis Research Studies

Palmoplantar pustulosis, also called PPP, is a chronic skin condition that causes pustules, scaling, redness, cracking, or discomfort on the palms of the hands and soles of the feet. Research studies may focus on therapies that reduce inflammation, improve skin texture, and help manage recurring symptoms.

Rosacea Research Studies

Rosacea is a chronic skin condition that may cause facial redness, flushing, visible blood vessels, bumps, pustules, burning, or skin sensitivity. Rosacea research studies may evaluate topical treatments, oral medications, light-based therapies, or other approaches designed to reduce redness and inflammatory flare-ups.

Skin Tightening Clinical Studies

Skin tightening clinical studies may focus on non-surgical treatments designed to improve the appearance of mild to moderate skin laxity. These studies may involve devices, injectables, topical products, or combination approaches used to support smoother, firmer-looking skin. Eligibility may depend on age, treatment area, skin type, and study requirements.

Psoriasis Research Studies

Psoriasis is a chronic inflammatory skin condition that can cause red, scaly, itchy, or painful plaques. Wilmington Dermatology Center has participated in various psoriasis research studies, including topical, injectable, and observational studies. Psoriasis clinical trials may evaluate new treatment options, long-term disease control, symptom improvement, and patient quality of life.

Inquire About Current or Future Dermatology Studies

Our research team regularly evaluates candidates for current and upcoming dermatology clinical research studies. Study availability, qualifications, time commitment, compensation, and treatment details vary by protocol. To learn whether you may qualify for a dermatology research study in Wilmington, NC, contact Wilmington Dermatology Center today.

Request an Appointment

Text Us

Detailed Listing of Clinical Research Studies Involving WDC

2025

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients with Moderate-to-Severe Atopic Dermatitis. Aclaris Therapeutics, Inc. 2025. Principal Investigator.
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Evaluating The Efficacy and Safety of EVO756 in Adults with Atopic Dermatitis. Evommune, Inc. 2025. Principal Investigator.
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK). Bristol Myers Squibb Company. 2025. Principal Investigator.
A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo in adult participants with moderate to severe platysma prominence in the United States. Merz North America Inc. 2025. Principal Investigator.
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars. AbbVie Inc. 2025. Principal Investigator.
A Prospective, Multi-Center, Randomized Controlled, Non-Inferiority Study to Evaluate Safety and Effectiveness of Ultraformer MPT PLUS Treatment to Lift Lax Submental (Beneath the Chin) and Neck Tissue. Classys Inc. 2025 Principal Investigator.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. Janssen Research & Development 2025. Principal Investigator.
Clinical study to assess tolerability and efficacy of facial brightening using Senté Vitamin C Product. Sente Inc. 2025. Principal Investigator.
Development of a Screening Tool in Platysma Bands – Prospective Validation Study. AbbVie Inc. 2025. Principal Investigator.

2024

A Phase 1 Study to Evaluate the Safety and Efficacy of Co-administration of TrenibotulinumtoxinE (AGN-151586) and OnabotulinumtoxinA (Botox) in Subjects for Treatment of Glabellar Lines (GL). AbbVie Inc. 2024. Principal Investigator.
A multicenter, double-blind, randomized, parallel-group, controlled study to evaluate the safety and effectiveness of ELAPR002f injectable gel in adult participants with atrophic acne scars. AbbVie Inc. 2024. Principal Investigator.
A Multicenter, Randomized, Double-blind, Double-dummy, Placebo- and Active-Comparator (Apremilast)-controlled Phase 3 Study to Evaluate the Efficacy and Safety of ME3183 in Subject with Moderate to Severe Plaque Psoriasis (BRING-1 Study). Meiji Pharma USA Inc. 2024. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 (ONWARD2). Alumis, Inc. 2024. Principal Investigator.
Multicenter, Randomized, Double-Blind, Placebo-controlled, Single-dose Phase 2 Study of the Safety and Efficacy of JTM201 (Botulinum toxin type A) to Treat Moderate or Severe Glabellar Lines. Jetema USA Inc. 2024. Principal Investigator.
BOTOX (onabotulinumtoxinA) for the Reduction of Masseter Muscle Prominence: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study. AbbVie Inc. 2024. Principal Investigator.
A Two-part, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis. Apogee Therapeutics. 2024. Principal Investigator.
A Randomized, Evaluator-blinded, Parallel group, Comparator-controlled, Multicenter study to Evaluate the Safety and Effectiveness of GP0116 for Correction of Moderate to Severe Dynamic Facial Wrinkles and Folds, such as Nasolabial Folds. Q-Med AB, Galderma. 2024. Principal Investigator.
A Phase 2a, Randomized, Double-blind, Placebo-Controlled, Proof-of-Concept Trial of ADX-914 for the Treatment of Severe Alopecia Areata. Q32 Bio Inc. 2024. Principal Investigator.
A Phase 3 Study of Tolerability, Safety, and Efficacy, of DMT310 in Patients with Acne Vulgaris. Dermata Therapeutics. 2024. Principal Investigator.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. Janssen Research & Development, LLC. 2024. Principal Investigator.

2023

A Randomized, Double-Blind, Vehicle-Controlled, Phase 2 Trial to Evaluate the Anti-Pruritic Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN008 in Adults with Mild to Moderate Atopic Dermatitis. TrialSpark, Inc. 2023. Principal Investigator.
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ANB032 in Treatment of Subjects with Moderate to Severe Atopic Dermatitis. AnaptysBio, Inc. 2023. Principal Investigator.
A randomized, no-treatment-control, evaluator-blinded, multi-center study to evaluate the effectiveness and safety of Restylane Contour in the treatment of temple hollowing. Q-Med AB, Galderma 2023. Principal Investigator.
Publication: JDD June 2023 – Volume 22 – Issue 6: Reduction of Erythema in Moderate-Severe Rosacea by a Low Molecular Weight Heparan Sulfate Analog (HSA). Rosalyn George MD, Richard L. Gallo MD PhD, Joel L. Cohen MD, Madeline Brown BS, Chidubem A. V. Okeke BS, Angel S. Byrd MD PhDA
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderate-to-severe Psoriasis. Ventyx Biosciences 2023. Principal Investigator.
A Phase 3, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab Monotherapy in Adult Subjects With Moderate-to-severe AD (ROCKET-Ignite). Amgen Inc. 2023. Principal Investigator.
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment.Janssen Research & Development, LLC. 2023. Principal Investigator.
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND).Amgen Inc. 2023. Principal Investigator.

2022

A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of Cedirogant (ABBV-157) in Adult Subjects with Moderate to Severe Psoriasis. AbbVie Inc. 2022. Principal Investigator.
Publication: George, R et al. A Randomized Trial to Assess Effectiveness and Safety of a Hyaluronic Acid Filler for Chin Augmentation and Correction of Chin Retrusion Plastic and Reconstructive Surgery: PRS Journal, Sept 2022
A Phase 2b, Multicenter, Randomized, Double-Blind, VehicleControlled, Parallel-Group Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of ATI-1777 in Patients 12 to 65 Years Old with Moderate or Severe Atopic Dermatitis (AD). Aclaris Therapeutics, Inc. 2022. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active and Placebo-Controlled Study to Assess the Safety, Efficacy, and Tolerability of Oral DFD-29 Extended Release Capsules for the Treatment of Inflammatory Lesions of Rosacea Over 16 Weeks. Dr. Reddy’s Laboratories Ltd. 2022. Principal Investigator.
A Phase 3, Multicenter Study to Evaluate the Safety and Efficacy of AGN-151586 for the Treatment of Glabellar Lines in Toxin-Naïve Subjects. AbbVie Inc. 2022. Principal Investigator.
Development of Patient Reported Outcome Measures in Fine Lines- Mixed Concept Elicitation and Cognitive Interviews. Allergan PLC. 2022.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of OnabotulinumtoxinA X for the Treatment of Moderate to Severe Glabellar Lines. AbbVie Inc. 2022. Principal Investigator.

2021

A Phase 2B, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects with Moderate to Severe Plaque Psoriasis. Nimbus Lakshmi, Inc. 2021. Principal Investigator.
A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Multiple Switches Between Humira® (adalimumab [US]) and ABP 501 Compared with Continued Use of Adalimumab in Subjects with Moderate to Severe Plaque Psoriasis. Amgen, Inc. 2021. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, with a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects with Moderate-to-Severe Alopecia Areata. Arena Pharmaceuticals, Inc. 2021. Principal Investigator.
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence. AbbVie, 2021. Principal Investigator.
Prospective, evaluator-blind, multicenter study to assess the safety and effectiveness of the Octave System treatment for improving lines and wrinkles on the décolleté. Ulthera. 2021. Principal Investigator.
A Multicenter, Randomized, Double-blind, Vehicle-Controlled, Phase 2a Study of TER-101 2.75% Topical Ointment to Assess Efficacy and Safety in Subjects with Mild to Moderate Atopic Dermatitis. Teres Bio., 2021. Principal Investigator.

2020

A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared with Continued Use of Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis. Amgen Inc. 2020. Principal Investigator.
A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared with Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis. Amgen, Inc. 2020. Principal Investigator.
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab when used in combination with Topical Corticosteroid Treatment in Patients with Moderate-to-Severe Atopic Dermatitis. Dermira Inc, 2020. Principal Investigator.
A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis. Dermira Inc, 2020. Principal Investigator.
A Prospective, Multicenter, Long-Term Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects. Galderma Research and Development, 2020. Principal Investigator.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L for the Treatment of Lateral Canthal Lines with or Without Concurrent Treatment of Glabellar Lines. Allergan, 2020. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Glabellar Lines. Galderma, 2020. Principal Investigator.
Development of Patient Reported Outcome Measures in Fine Lines – Mixed Concept of Elicitation and Cognitive Interviews (AGN 1418). Allergan PLC, 2020. Principal Investigator.

2019

A Random, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-severe atopic dermatitis. Dermira, 2019. Principal Investigator.
A Randomized, evaluator-blinded, parallel group, no treatment controlled multi-center study to evaluate the safety and effectiveness of Restylane-L for correction of Infraorbital Hollows. Galderma. 2019. Principal Investigator.
A Phase 2b Double-Blinded, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of AGN-151586 in Participants with Moderate to Severe Glabellar Lines. Allergan. 2019. Principal Investigator.
A Phase 3 Efficacy and Safety Study of Tapinarof Topical for the Treatment of Plaque Psoriasis in Adults. Dermavant Sciences GmbH. 2019. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis. Abbvie. 2019. Principal Investigator.
A Phase 2, randomized, placebo-controlled, double-blind, multiple dose study to evaluate the efficacy and safety of ANB019 in subjects with Palmoplantar Pustulosis. AnaptysBio Inc. 2019. Principal Investigator.
A Phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study investigating the efficacy, safety, and pharmacokinetic profiles of REGN3500 administered to adult patients with moderate-to-severe atopic dermatitis. Regeneron Pharmaceuticals, Inc. 2019. Principal Investigator.

2018

A phase II, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Calcipotriene and Betamethasone Dipropionate Topical Foam to the Marketed Product Enstilar Foam in the Treatment of Psoriasis Vulgaris. Glenmark Pharmaceuticals, 2018. Principal Investigator.
A Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of topical tranexamic acid in a novel transdermal delivery system for improvement of melasma. Dyve Biosciences, 2018. Principal Investigator.
A Randomized, No-Treatment Controlled, Evaluator-Blinded, Multicenter Study to Evaluate the Effectiveness and Safety of Restylane® Defyne in the Chin for Augmentation and Correction of Chin Retrusion. Nestle Skin Health, 2018. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Secukinumab-controlled, parallel-group study to evaluate the efficacy and safety of Bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis. UCB Biosciences, 2018. Principal Investigator.
A Randomized, Double-Blind, Placebo-Controlled, efficacy study of the Neurokinin-1 receptor antagonist VLY-686 in patients with Atopic Dermatitis. VANDA, 2018. Principal Investigator.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging study investigating the Efficacy, Safety and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects with Moderate-to-Severe Atopic Dermatitis. AnaptsysBio, 2018. Principal Investigator.
A Randomized, Double-Blind, Placebo-controlled, Dose-ranging trial to evaluate the efficacy and safety of Lebrikizumab in patients with Moderate-to-severe Atopic Dermatitis. Dermira, 2018. Principal Investigator.
Efficacy, Safety and Durability of Response of BMS-986165 Versus Placebo and Active Comparator in Subjects with Moderate-to-Severe Plaque Psoriasis. BMS, 2018. Principal Investigator.
A Randomized, Double-Blind, Placebo-controlled, Multicenter, 24-week Study to Assess the Efficacy and Safety of PPC-06 (Teplilamide Fumarate) Extended Release Tablets in Subjects with Moderate-to-Severe Plaque Psoriasis. Novella, 2018. Principal Investigator.

2017

Randomized, Double-Blind Comparison Pilot Study Evaluating the Safety and Efficacy of Tranexamic Acid, in a Novel Transdermal Delivery System, Compared to Hydroquinone for Improvement of Melasma. AmperSand Biopharmaceuticals, LLC 2017. Principal Investigator.
Double-Blind, Controlled, Pilot Study Evaluating the Safety and Efficacy of Percorium-Delivered Bimatoprost and Minoxidil for the Treatment of Alopecia Androgenetica (Male Pattern Hair Loss). AmperSand Biopharmaceuticals, LLC 2017. Principal Investigator.
A Multicenter, Open Label Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis. AbbVie 2017. Principal Investigator.

2016

A Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel-Group, Dose Ranging Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis. UCB Biosciences, Inc. 2016. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Foam, 0.05% Versus Vehicle Foam In Subjects with Plaque Psoriasis. Therapeutics 2016. Principal Investigator.
Non-Inferiority Study of the Safety and Efficacy of Ultherapy for Lifting and Tightening the Face and Neck Using Standard vs. Simulines Transducers. Ulthera Inc. 2016. Principal Investigator
BI 655066 versus Ustekinumab and placebo comparators in a randomized double-blind trial for Maintenance use in Moderate to severe plaque type psoriasis-2 (UltMMa-2). Boehringer Ingelheim Pharmaceuticals, Inc. 2016. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Tadipitant in Treatment-Resistant Pruritus Associated with Atopic Dermatitis. Vanda Pharmaceuticals Inc. 2016. Principal Investigator.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Tacrolimus Ointment, 0.1% (Glenmark Generics, Ltd) to the Marketed Product Protopic (tacrolimus) ointment, 0.1% (Astellas Pharma US, Inc.) in the Treatment of Moderate to Severe Atopic Dermatitis. Novum Pharmaceutical Research Services, 2016. Principal Investigator.

2015

Pilot Study Site: Non-Inferiority Study of the Safety and Efficacy of Ultherapy for Lifting and Tightening the Face and Neck Using Standard vs. Simulines Transducers. Ulthera Inc. 2015. Principal Investigator.
A Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis. Lilly USA LLC. 2015. Principal Investigator.
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 1.5mg/kg per Day or Sarecycline Compared to Placebo in the Treatment of Acne Vulgaris. Actavis. 2015. Principal Investigator.
Multi-center non-interventional study to collect information on the condition of submental (SM) fullness due to submental fat (SMF), how it is treated in current clinical practice, and the risks and benefits associated with its treatment. Kythera Biopharmaceuticals, Inc. 2015. Principal Investigator.
A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilumab Monotherapy Administered to Adult Patients with Moderate-to-Severe Atopic Dermatitis. Regeneron Pharmaceuticals, Inc. 2015. Principal Investigator.
A Multi-center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo New York Inc’s Ingenol Mebutate Topical Gel 0.05% to Leo Pharma Inc. Picato Topical Gel 0.05% (Ingenol Mebutate Topical Gel 0.05%) and Both Active Treatment to a Vehicle Control in the Treatment of Actinic Keratosis on the Trunk and Extremities. Perrigo New York, Inc.,2015. Principal Investigator.
A Randomized, Double-Blind, Parallel Design, Multiple-Site Study to Evaluate the Therapeutic Equivalence of Diclofenac Sodium Gel 3% (Taro Pharmaceuticals USA., Inc.) Compared to Solaraze 3%, gel (diclofenac sodium 3% w/ Almirall, S.A.) in the Treatment of Actinic Keratosis. Novum Pharmaceutical Research Services, 2015. Principal Investigator.
Evaluation of the safety and efficacy of the Ulthera System for the treatment of signs and symptoms of Erythemototelangiectatic Rosacea. Ulthera Inc. 2015. Principal Investigator.

2014

Vacation Dermatoses. Jessica Connett, MD and Rosalyn George, MD, JAAD Vol 70, Num 5, 961-963, May 2014.
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Study followed by a dose-blind period and open-label follow-up to evaluate the efficacy and safety of Certolizumab Pegol in subjects with moderate to severe chronic plaque psoriasis. Dermira. 2014. Principal Investigator.
A Randomized double-blind, multicenter study to demonstrate equivalent efficacy and to compare safety and immunogenicity of a biosimilar adalimumab and Humira in patients with moderate to severe chronic plaque-type psoriasis. Sandoz. 2014. Principal Investigator.
A Safety and Efficacy Study to Compare Dapsone Dermal Gel with Vehicle Control in Patients with Acne Vulgaris. Allergan. 2014. Principal Investigator.
An Observational, multicenter disease registry to evaluate clinical practice trends and outcomes in adult patients with Hidradenitis Suppurativa. AbbVie Inc. 2014. Principal Investigator.

2013

A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Lotion 0.05% versus Vehicle Lotion in Subjects with Plaque Psoriasis. Therapeutics. 2013. Principal Investigator.
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to determine the Therapeutic Equivalence of Generic Imiquimod Cream, 2.5% and Zyclara (Imiquimod) Cream 2.5% in Subjects with Actinic keratoses. Therapeutics. 2013. Principal Investigator.
A Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of M518101 in Subjects with Plaque Psoriasis. Maruho North America. 2013. Principal Investigator.
A Randomized, Double-Blind, Multiple-Site, Placebo-controlled, Parallel Design Study comparing Diclofenac Sodium Gel 3% (Actavis) to Solaraze (diclofenac) Gel 3% in the Treatment of Actinic Keratosis. Actavis. 2013. Principal Investigator.

2012

A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis. Eli lilly Co. 2012 to present. Principal Investigator.

2011

A 10-Year, Post-marketing, Observational, Registry of HUMIRA (Adalimumab) in Adult Patients with Chronic Plaque Psoriasis (Ps). Abbott Laboratories. December 2011 to present. Principal Investigator.
An Evaluation of the Burden of Illness Among Adults with Moderate-to-Severe Plaque Psoriasis Seeking Care in the United States. Pfizer. 2011- 2012. Principal Investigator.
A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Multi-Center Phase IIb Dose Finding Study of M518101 in Plaque Psoriasis Patients. Maruho Co., Ltd. 2011 2012. Principal Investigator.

2009

Efficacy and Safety of Alitretinoin in the Treatment of Severe chronic Hand Eczema Refractory to Topical Therapy. Basilea Pharmaceuticals. June 2009-Present. Principal Investigator.

2008

George R, Clarke S, Ioffreda M, Billingsley E. Marking of nail matrix biopsies with ink aids in proper specimen orientation for more accurate histologic evaluation. Dermatologic Surgery Vol 32, number 12, 1705-1706, Dec 2008.

2007

Study on interest in cosmetic procedures in patients visiting an academic dermatology group. Penn State Milton S. Hershey Medical Center, 2007
Clarke S, Nelson A, George R, Thiboutot D. Pharmacologic Modulation of Sebaceous Gland Activity: Mechanism’s and Clinical Applications. Dermatologic Clinics: Drug Actions, Reactions and Interactions. Dermatologic Clinics. April 2007
Rosalyn George, MD, Gregory J. Fulchiero, Jr, MD, MSBioEng, James G. Marks, Jr, MD, Jennie T. Clarke, MD. Neurovascular Instability Syndrome: A Unifying Term to Describe the Coexistence of Temperature-Related Vascular Disorders in Affected Patients. Arch of Dermatol Vol 143, 274-275, (2007).
Jennie T. Clarke MD, Harper Price MD, Shari Clarke MD, Rosalyn George MD, Jeffrey J. Miller MD. Case Reports: Acquired Kinking of the Hair Caused by Acitretin. Journal of Drugs in Dermatology Vol 6, Issue 9, 937-938 (2007).

2006

Study to determine the ideal biopsy site for lentigo maligna. Penn State Milton S. Hershey Medical Center, 2006-present
George R. Commentary on May 2007 JAAD article Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. Published on Dermlink.net
George R. Commentary on September 2006 NEJM article Sentinel-node biopsy or nodal observation in melanoma. Published on Dermlink.net

2003

Populous Papules. George R, Nunley J., Cortlandt Forum 2003;16(8): 46-49.

1998-99

Study on the effects of P450 enzymes in the conversion of chlorpyrifos to chlorpyrifos-oxon. Virginia Maryland Regional College of Veterinary Medicine, 1998-1999